|
Impact of prophylactic treatments of cetuximab-based skin reactions in patients with metastatic colorectal carcinoma (mCRC): Interim analysis of the German noninterventional study ERBITAG. |
|
|
Stock and Other Ownership Interests - Fresenius; Merck KGaA |
|
Research Funding - Merck Serono (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
Christiane Hering-Schubert |
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Mundipharma; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Novartis |
|
|
Employment - Merck Serono |
|
Alma Katharina Steinbach-Buechert |
Employment - Merck KGaA (I); Merck Serono |
|
|
No Relationships to Disclose |